Showing results (691-700 of 1,395) with videos related to

Sort By:
Pageof 140
JCO Precision Oncology|April 23, 2026
Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic ToxicityMitchell Parma, Kaiwen Wang, Ceylan Altintas Taslicay, et al.
JCO Precision Oncology|April 16, 2026
Germline Pathogenic Variants in Homologous Recombination Pathway Genes Are Frequent in Pancreatobiliary Ampullary CarcinomaMaksym Misyura, Pier Selenica, Kerem Ozcan, et al.
JCO Precision Oncology|April 9, 2026
Prognostic Value of MammaPrint in Diverse Populations: Evaluating Racial Disparities in Breast Cancer OutcomesReine Abou Zeidane, Samuel Lichtman-Mikol, Courtney Pisano, et al.
JCO Precision Oncology|April 9, 2026
Evaluating Tumor Burden as a Predictive Biomarker for Epidermal Growth Factor Receptor Targeted Kinase Inhibitor Therapy in Advanced Non-Small Cell Lung CancerRika Terashima, Judy Fan, Fatma Gunturkun, et al.
JCO Precision Oncology|March 18, 2026
Therapeutically Targetable Mutational Landscape of Anaplastic Thyroid CancerMurtaza Qazi, Muhammad Danyal Ahsan, Talar Telvizian, et al.
JCO Precision Oncology|March 25, 2026
Concordance of Circulating Tumor DNA, Primary and Metastatic Tissue DNA, and Immunohistochemistry in Gastroesophageal CarcinomaFares Jamal, Oudai Sahwan, Seyi Abidoye, et al.
JCO Precision Oncology|April 3, 2026
Survival in Patients With Low Expression of Wild-Type Homologous Recombination Genes: Refining the Homologous Recombination Paradigm in Colorectal CancerDaniel Walden, Felipe Batalini, Cody Eslinger, et al.
JCO Precision Oncology|July 10, 2026
Real-World Genomic Characteristics and Prognostic Association in Advanced Papillary Thyroid CarcinomaSoji Toda, Yukihiko Hiroshima, Hiroyuki Iwasaki, et al.
JCO Precision Oncology|July 10, 2026
Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract CancersPriyanshi Shah, Anina Peersen, Vaibhav Sahai, et al.
JCO Precision Oncology|July 6, 2026
Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision StudyLore Decoster, Philippe Aftimos, Sylvie Rottey, et al.
Pageof 140